Drug Safety Update

Rybelsus ® (semaglutide tablets): transition to new formulation and risk of medication error

Issued 17 Dec 2025

Read and act on the official notice on GOV.UK

The MHRA's summary

There is a risk of patient harm arising through medication error during a transition period where the original and new formulation of Rybelsus ® tablets, which have different stated mg doses but are bioequivalent, will both be available on the market.

MHRA's audience tags: Care home staff, Dispensing GP practices, Endocrinology diabetology metabolism, General practice, Gi hepatology pancreatic disorders, Nutrition dietetics, Pharmacy

Pharmshark is not an official alerting route. Make sure your pharmacy receives alerts directly from the MHRA and through your organisation, and always act on the official GOV.UK notice.

Source: the MHRA on GOV.UK. Contains public sector information licensed under the Open Government Licence v3.0. Pharmshark is not affiliated with or endorsed by the MHRA.